Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of heterologous 2-dose Ebola vaccine regimens Ad26.ZEBOV and MVA-BN-Filo
PACTR201608001734218Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 5
01
Overview
Phase 2, randomised trial of zabdeno and Mvabea in Ebola virus disease (EVD) (6 arms), sponsored by Janssen Pharmaceutical. Started Nov 2015; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR201608001734218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201608001734218.